Trump fast-tracks psychedelics as mental health medicine through federal agencies
Executive order directs FDA to expedite clinical access while reevaluating controlled substance classifications.
President Trump signed an executive order on April 18, 2026, directing federal agencies to "reverse the crisis of serious mental illness in America" by accelerating psychedelic drug access in clinical settings. The order instructs the FDA to fast-track certain psychedelics as breakthrough therapies and expand access through right-to-try legislation, which allows terminally ill patients to use experimental treatments outside standard regulatory pathways. STAT reported the administration will simultaneously reevaluate the controlled substance status of these compounds.
This follows the exact trajectory of cannabis legalization over the past decade. Medical necessity created the initial wedge, followed by federal policy shifts that legitimized what was once underground. For years, the assumption was that psychedelics would remain relegated to fringe wellness circles and underground therapy. That assumption has collapsed as mental health crises demand new solutions. The same federal machinery that once criminalized these substances now positions them as breakthrough medical tools. Political expedience has transformed Schedule I drugs into potential prescription medicines within a single executive signature.
When government fast-tracks your consciousness, the line between medicine and optimization disappears entirely.
Prepare for psychedelics to enter mainstream wellness infrastructure within 18 months. Federal legitimization will accelerate corporate adoption, insurance coverage, and consumer normalization faster than organic cultural acceptance ever could.
Source: STAT